Partial PPARγ agonists, such as FK614,that differentially activate PPARγ target genes may beeffective in treating metabolic disease while reducing the sideeffects (e.g., promoting obesity) caused by current TZD-basedtreatments. This evidence concerns the gene PPARG and obesity disorder.